Skip to main content
Premium Trial:

Request an Annual Quote

DNA2.0, Blue Sky Biotech Ink Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Synthetic genomics company DNA2.0 said today that it has forged a strategic alliance agreement with the contract research organization Blue Sky Biotech to provide integrated gene synthesis and protein expression and purification services.

Menlo Park, Calif.-based DNA2.0 said that its custom gene synthesis technology enables researchers to redesign entire gene sequences in order to maximize the likelihood of high protein expression, easy genetic manipulation, and convenient protein purification.

"The alliance with DNA2.0 enhances our production capacity in molecular biology and provides access to DNA2.0's patented technologies," Blue Sky Chief Scientific Officer Norman Garceau said in a statement. "By partnering, our clients will be able to save significant time and receive high-quality solutions."

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.